Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QuestCor QSC -- Ignore unavailable to you. Want to Upgrade?

To: Philip Aaron Etttedgui who wrote (60)	10/31/1997 12:06:00 PM
From: Dennis C	Read Replies (1) \| Respond to of 120

Cypros Pharmaceutical Presents Promising Pre-Clinical Data on Novel New Drugs for the Treatment of Stroke CARLSBAD, Calif.--(BW HealthWire)--Oct. 31, 1997--Scientists from Cypros Pharmaceutical Corporation (NASDAQ:CYPR) reported this week at the Annual Meeting of the Society for Neuroscience in New Orleans that the Company's novel, neuronal calcium channel blockers demonstrated profound protection of brain tissue when administered post-stroke in an animal model. These novel non-peptide, small molecule compounds were discovered by Cypros chemists. These compounds are the subject of United States and European patent applications filed earlier this year. Cypros scientists have spent three years developing these novel agents that inhibit the release of the neurotransmitter glutamate. Excess glutamate release causes brain damage after stroke episodes. Current strategies of blocking glutamate receptors have not been successful as stroke therapeutics. Reducing excess glutamate release is a new approach to stroke therapy and the Cypros compounds represent a new class of non-peptide agents that hold promise for the treatment of a variety of neurologic and psychiatric disorders whose underlying pathophysiology involve excess neurotransmitter release. Commenting on the new data, Dr. Paul Marangos, Chief Executive Officer of Cypros, stated, ''We have focused on presynaptic control of glutamate release in all our research programs and are pleased that our focused group of scientists have synthesized a variety of agents which regulate glutamate released from nerve cells and glial cells. The clinical potential of the nerve cell specific agents reported on in New Orleans is substantial and represents a breakthrough for this program.'' Cypros Pharmaceutical Corporation is engaged in the development and marketing of drug products for the hospital market. The Company is pursuing a diversified strategy of marketing approved drugs and developing small molecule therapeutics that protect cells from ischemic injury. Ischemia is the number one cause of death in most developed countries. The Company currently has three products on the market, Glofil, Inulin and Ethamolin(R).